Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor

NCT02426086 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

107

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelofibrosis

Interventions

DRUG: Imetelstat 4.7 mg/kg
DRUG: Imetelstat 9.4 mg/kg

Sponsor

Geron Corporation